Twist Bioscience Posts Record Quarterly Revenue of $126.6 Million
Key Facts
Twist Bioscience reported record revenue of $126.6 million in the fourth quarter of fiscal 2026, up nearly 28% from the same period a year earlier. The company also said it had posted sequential revenue growth for 15 consecutive quarters. The results were included in a company statement issued on November 12, after it had previously scheduled the release ahead of the market open. Revenue in the fourth quarter of fiscal 2025 was $99.0 million, according to the earnings statement. For the full fiscal year, revenue reached $459.4 million, up 22% from $376.6 million in fiscal 2025. The figures show growth extending from the quarterly comparison to the annual one, as the company continued to post sequential revenue gains.
Fourth-quarter revenue exceeded the range the company forecast in August, when it estimated revenue of $123 million to $124 million for the quarter and raised its fiscal 2026 outlook to $456–457 million. Full-year revenue came to $459.4 million, according to the earnings statement, while quarterly revenue was $126.6 million. In the third quarter of fiscal 2026, the company reported revenue of $118.4 million, up more than 23% from the third quarter of fiscal 2025. The quarterly comparison shows revenue rising again in the fourth quarter after the third-quarter result. In fiscal 2025, revenue had risen to $376.6 million from $313.0 million in fiscal 2024.
Gross margin improved to 53.1% in the fourth quarter from 51.3% in the same period of fiscal 2025. For the full fiscal year, the margin was 52.4% in 2026, compared with 50.7% in 2025. The company also recorded positive adjusted EBITDA of $2.2 million for the quarter, after an adjusted loss of $7.8 million in the comparable period. Quarterly net loss, however, was $20.6 million. The measures reflect improved margins and adjusted results alongside a continuing net loss for the quarter.
By business unit, revenue from DNA Synthesis and Protein Solutions rose 33% to $61.0 million in the fourth quarter, while revenue from NGS Applications increased 24% to $65.7 million. In fiscal 2026, revenue from the first unit grew 31.7% to $221.9 million, and revenue from NGS Applications rose 14.1% to $237.5 million. The company shipped products to about 4,100 customers in fiscal 2026, compared with about 3,800 in the prior year. It also shipped about 1.3 million genes, versus about 938,000 genes in fiscal 2025. The figures put the expansion in customers and shipment volume alongside revenue growth in both business units.
The company forecast revenue of $550 million to $560 million for fiscal 2027, equivalent to growth of about 21% at the midpoint, and said the guidance assumes $100 million in AI drug discovery revenue. It also set a gross margin range of 52.5% to 53% and estimated capital expenditures of about $75 million as part of a two-year investment plan. For the first quarter of fiscal 2027, it forecast revenue of $130 million to $132 million, representing year-over-year growth of about 26% at the midpoint, with sequential growth continuing. Chief Executive Emily Leproust said the company was entering the new fiscal year "with a stronger business and the capital needed to invest in the next phase of growth." She added that AI is expanding what scientists can design and that personalized medicine is increasing demand for unique molecules.
Twist ended the fiscal year on September 30, 2026, with about $582 million in cash, cash equivalents and short-term investments, and said it raised net proceeds of about $425 million through an equity offering and at-the-market sales during the year. Before the results were released, the company had announced that its fourth-quarter and fiscal-year report would be issued ahead of the market open on November 12, with the investor call beginning at 8:00 a.m. Eastern time. TWST shares closed at $122.59 on November 11, according to EL7 data. The company is scheduled to participate in the Jefferies Global Healthcare Conference on November 17, followed by the Evercore Healthcare Conference on December 1. Those dates follow the results announcement and financial guidance for the new fiscal year.